11. Procalcitonin-Guided Antibiotic Discontinuation (ADAPT-Sepsis Update)

Quick Recap

Cross-cutting protocol — companion to Antimicrobial Duration — Short-Course Therapy in Critical Illness and Antimicrobial Dosing & TDM protocols. Addresses biomarker-guided (procalcitonin, and comparatively, C-reactive protein) antibiotic discontinuation — a distinct approach from the fixed-duration RCT evidence covered in the Antimicrobial Duration protocol — culminating in the large, methodologically superior 2025 ADAPT-Sepsis trial, which found a genuinely important, shrinking effect as fixed short-course practice has itself become standard.

1. Definition

Procalcitonin (PCT)-guided antibiotic discontinuation: an algorithm-based approach using serial PCT measurements (typically daily) to inform decisions about stopping antibiotic therapy, based on either an absolute threshold (e.g., <0.5 µg/L) or a substantial relative decline from peak value (e.g., ≥80% decrease) — distinct from the fixed-duration approach (cross-reference Antimicrobial Duration protocol), which assigns a predetermined calendar-based course length regardless of biomarker trajectory.

C-reactive protein (CRP)-guided discontinuation: an analogous biomarker-based algorithm using CRP trend rather than PCT — tested head-to-head against PCT and standard care in the most recent, definitive trial (ADAPT-Sepsis, Section 11), with a materially different result from PCT.

Why this is conceptually distinct from the fixed-duration evidence base: fixed-duration trials (BALANCE, STOP-IT, cross-reference Antimicrobial Duration protocol) ask "is a shorter predetermined course non-inferior to a longer predetermined course?" Biomarker-guided trials ask a different question: "can an individualized, biologically-responsive signal safely shorten therapy on a patient-by-patient basis, potentially below or above a fixed course, tracking the patient's actual inflammatory trajectory?" These are complementary but distinct stewardship strategies, and the evidence for one does not automatically validate the other.

2. Pathophysiology

Procalcitonin is a precursor peptide of calcitonin, produced in response to bacterial infection via a pathway distinct from the general acute-phase inflammatory response — its production is specifically induced by bacterial endotoxin and pro-inflammatory cytokines, and (unlike CRP) tends to be relatively suppressed by viral infection, providing a theoretically more specific signal for ongoing bacterial infection activity than the broader, less specific acute-phase reactant CRP. As bacterial infection resolves (with or without antibiotic treatment), PCT levels are expected to decline in a kinetic pattern that can, in principle, inform when the biological driver of infection has been adequately addressed — the mechanistic rationale for using its trajectory, rather than a fixed calendar duration, to guide discontinuation timing.

Why the evidence has evolved as it has: PCT's specificity advantage over CRP is real but incomplete — elevated PCT can occur in several non-infectious critical illness states (major surgery, trauma, certain malignancies), and declining PCT does not perfectly track clinical cure. This imperfect specificity, combined with methodological limitations in earlier trials (open-label design allowing clinician bias, inconsistent algorithm adherence), has been a persistent source of uncertainty regarding how much of the observed benefit reflects PCT's true biological signal versus other trial-design factors — a tension the most recent, more rigorously designed trial (ADAPT-Sepsis) was specifically built to address.

3. Immediate Stabilization (ABCDE) — Not Applicable in the Traditional Sense

This protocol addresses an ongoing-treatment monitoring and discontinuation decision rather than acute stabilization; the relevant "checklist" is a biomarker-monitoring framework applied once appropriate empiric/targeted antibiotic therapy has been initiated:

Checklist:

4. Focused History

• Infection source and organism (relevant to which specific evidence base — fixed-duration vs. biomarker-guided — is most applicable)
• Baseline PCT/CRP trajectory since treatment initiation
• Concurrent non-infectious drivers of biomarker elevation (major surgery, trauma) that may confound interpretation
• Current planned fixed-duration course length, if already established per Antimicrobial Duration protocol — relevant to understanding how much additional value biomarker guidance can plausibly add on top of an already-short course (Section 11)

5. Comprehensive System-wise Examination

Not a primary examination-driven protocol; relevant findings are the overall clinical trajectory (fever curve, hemodynamic stability, organ function trend) that should be interpreted alongside, not instead of, the biomarker trend.

6. Syndrome Identification — Reframed as Applicability Classification

• Suspected sepsis, antibiotics initiated within 24 hours, expected duration ≥72 hours, baseline (~7-day) fixed-course practice environment: the population and practice context specifically studied in ADAPT-Sepsis — PCT guidance may offer modest additional stewardship benefit in this setting (Section 11)
• Practice environment already using aggressively short (e.g., BALANCE-informed 7-day) fixed-duration protocols: current evidence suggests biomarker guidance's incremental value may be genuinely diminished when compared against an already-short baseline course, rather than the longer historical courses against which earlier biomarker trials (PRORATA, SAPS) were tested
• Non-bacteremic, broader ICU population with suspected sepsis but no confirmed bloodstream infection: the population ADAPT-Sepsis specifically targeted, distinct from the confirmed-bacteremia population in BALANCE

7. Differential Diagnosis — Not a Traditional Differential

Cross-reference Sepsis Bundles & Source Control protocol for the underlying differential of the infectious process itself; this protocol's relevant consideration is distinguishing a genuinely declining biomarker reflecting resolving infection from a biomarker decline that may not fully reflect ongoing, inadequately treated infection (particularly where source control remains incomplete).

8. Severity/Risk Assessment

Not a severity-scoring protocol; relevant consideration is algorithm adherence itself as a determinant of realized benefit — across the trial literature, adherence to the PCT-guided discontinuation advice has been consistently suboptimal (a recurring limitation explicitly noted in ADAPT-Sepsis and predecessor trials), meaning the intention-to-treat effect size in these trials likely understates the biomarker's biological signal to some degree, while simultaneously reflecting genuine real-world implementation challenges that limit the practically achievable benefit.

9. Investigations

Immediate bedside: not applicable

Routine labs: serial PCT (daily, per major trial protocols) as the primary "investigation" this protocol addresses; CRP as a comparative, generally less effective alternative per the most recent head-to-head evidence (Section 11)

Repeat frequency: daily measurement, consistent with all major trial protocols (PRORATA, SAPS, ADAPT-Sepsis)

10. Point-of-Care Ultrasound — Not Applicable

11. Evidence-Based Management — The Evolving Evidence Base

Early Trials — Establishing Feasibility with Genuine Safety Concerns

• PRORATA trial (Bouadma et al., Lancet 2010): PCT-guided care reduced median antibiotic duration (11.6 vs. 14.3 days) with no statistically significant mortality difference, but a concerning, though non-significant, trend toward higher mortality in the PCT arm — this trend generated genuine, persistent safety concern in the field for years afterward, despite not reaching statistical significance
• SAPS trial (de Jong et al., Lancet Infect Dis 2016, n=1,546, 15 Dutch hospitals): using a similar PCT threshold to PRORATA — reduced antibiotic duration (5 vs. 7 days, p<0.0001) and, notably, lower 28-day mortality in the PCT-guided arm (20% vs. 25%) — this result specifically alleviated the mortality concern raised by PRORATA, though the mechanism for the mortality difference was not definitively established (the study authors speculated that PCT feedback might prompt earlier consideration of alternative, non-infectious diagnoses when levels were unexpectedly low, though this remains speculative rather than mechanistically confirmed)
• ProGUARD trial (2014, n=400, 11 Australian ICUs): using a stricter PCT threshold than PRORATA — failed to show a significant reduction in antibiotic duration (9 vs. 11 days, p=0.58) despite very high algorithm adherence (>97%) — illustrating that threshold choice itself materially affects whether a detectable stewardship benefit is realized, a genuine source of between-trial heterogeneity
• Patient-level meta-analyses (2018, pooling multiple trials including PRORATA and SAPS, n≈4,482): found PCT-guided care associated with significantly lower mortality (21.1% vs. 23.7%, adjusted OR 0.89, 95% CI 0.80–0.99, p=0.03) and reduced antibiotic duration (9.3 vs. 10.4 days) — a reassuring, statistically significant pooled signal that substantially resolved the PRORATA-era safety concern at a population evidence level, though this remains a meta-analytic (not single definitive trial) conclusion

ADAPT-Sepsis (2025) — The Definitive, Methodologically Superior Recent Trial

• ADAPT-Sepsis trial (Dark et al., JAMA 2025, n=2,760, 41 UK NHS ICUs, January 2018–June 2024): a three-arm, intervention-concealed (a key methodological advance over the open-label design of earlier trials, since clinicians could not simply request PCT off-protocol, reducing contamination/bias) RCT comparing daily PCT-guided, daily CRP-guided, and standard care antibiotic discontinuation protocols in critically ill adults with suspected sepsis
• Result: PCT guidance reduced antibiotic duration by approximately 10% vs. standard care (an absolute reduction of only ~1 day, specifically 1.13 days for PCT vs. 0.71 days for CRP during the initial sepsis period) — statistically detectable but modest in absolute magnitude
• CRP guidance showed no meaningful benefit — a clear, direct head-to-head finding that PCT outperforms CRP for this specific application, resolving prior ambiguity about whether the cheaper, more widely available CRP could serve as an adequate substitute (it cannot, per this trial)
• No significant mortality difference between PCT-guided care and standard care on the primary safety outcome (28-day all-cause mortality), though a numerical 1.5% mortality increase in one reported analysis is flagged in commentary as warranting some continued caution rather than being dismissed outright
• Algorithm adherence was again suboptimal, consistent with the pattern across nearly the entire trial literature in this specific area — a persistent, unresolved implementation challenge rather than a one-off limitation of any single trial

The Central, Genuinely Important Interpretive Point — A Shrinking Effect in an Era of Shorter Fixed Courses

• ADAPT-Sepsis's much more modest absolute benefit (~1 day) compared to earlier trials' larger differences (PRORATA: 2.7 days; SAPS: 2 days) is best explained by the changing baseline standard of care itself: as fixed short-course antibiotic therapy has become increasingly standard practice (cross-reference Antimicrobial Duration protocol's BALANCE trial and broader short-course evidence, largely developed and adopted in the years between the earlier PCT trials and ADAPT-Sepsis), the "usual care" comparator against which PCT guidance is being tested has itself become shorter and more disciplined — leaving progressively less room for a biomarker-guided algorithm to further shorten an already-short course
• This is a directly analogous evidence-interpretation pattern to the ACURASYS-vs-ROSE discordance in the Neuromuscular Blockade in ARDS protocol: an intervention's measured benefit can appear to diminish over time not because the intervention's underlying biological signal has weakened, but because the comparator/standard of care it's being tested against has independently improved — worth recognizing as a recurring pattern in evidence interpretation across this library, not unique to antibiotic stewardship
• Direct expert conclusion from a dedicated 2026 reassessment of this exact question (Gupta, Klompas, Rhee, Clin Infect Dis 2026): "as shorter fixed-duration therapy becomes standard, procalcitonin's utility in the intensive care unit may decline" — an explicit, authoritative statement that PCT-guided therapy's future clinical value is likely to keep shrinking as fixed-course stewardship (per the Antimicrobial Duration protocol's evidence base) becomes further entrenched, rather than PCT guidance being an permanently stable, independent stewardship tool

Practical Synthesis

Procalcitonin-guided antibiotic discontinuation is a reasonably safe stewardship tool with a modest, and likely diminishing, incremental benefit on top of current fixed short-course practice. CRP guidance has not shown comparable benefit and should not be considered an adequate substitute for PCT specifically. Given consistently suboptimal algorithm adherence across the entire trial literature, and the explicit expert conclusion that PCT's marginal value is likely shrinking as fixed-duration stewardship matures, institutions should view PCT guidance as one component within a broader, multifaceted antimicrobial stewardship strategy (cross-reference Antimicrobial Duration and Sepsis Bundles & Source Control protocols) rather than as a standalone, independently sufficient duration-determining tool. Future research priority, per the most recent authoritative commentary, should shift toward earlier biomarker use in the sepsis care pathway (e.g., Emergency Department diagnostic/triage decisions) rather than continued ICU-focused discontinuation-timing trials, where the marginal value proposition is becoming progressively narrower.

12. Organ Support

Not applicable; this is a diagnostic-biomarker/stewardship protocol rather than an organ-support one.

13. Disease-Specific Therapy — Not Applicable

This protocol addresses a monitoring/discontinuation-decision framework rather than a specific pharmacotherapy regimen; cross-reference Antimicrobial Duration and Antimicrobial Dosing & TDM protocols for the underlying antibiotic selection, dosing, and duration frameworks this biomarker guidance supplements.

14. Consultation Matrix

15. Monitoring Framework

• Laboratory: daily PCT (preferred over CRP per ADAPT-Sepsis head-to-head evidence) trend from baseline
• Clinical: overall trajectory interpreted alongside, not instead of, the biomarker trend
• Escalation triggers: biomarker rising or failing to decline despite adequate source control and appropriate antibiotic therapy → reassess for treatment failure, resistant organism, or an unaddressed source, per Sepsis Bundles & Source Control and Antimicrobial Dosing & TDM protocols, rather than mechanically extending therapy based on the biomarker number alone

16. ICU Bundle Checklist

17. Complications

Of over-reliance on biomarker guidance without clinical correlation:

• Premature discontinuation in a patient with declining biomarker but incomplete source control or unrecognized ongoing infection
• False reassurance from a biomarker trend that does not fully reflect the true clinical trajectory, particularly given PCT's imperfect specificity in surgical/trauma/malignancy contexts

Of the biomarker-guided approach itself, per trial evidence:

• No clearly established excess harm signal in the current, most rigorous trial (ADAPT-Sepsis), though the PRORATA-era mortality trend concern, while substantially resolved by SAPS and subsequent meta-analyses, is a reminder that this area has not been entirely free of safety signal throughout its evidence history

Prevention: integrating biomarker trend with clinical and source-control assessment, not applying it in isolation

Rescue: standard reassessment for treatment failure per Sepsis Bundles & Source Control and Antimicrobial Dosing & TDM protocols if clinical concern persists despite a favorable biomarker trend

18. Escalation & De-escalation

Escalation: biomarker rising or plateauing despite adequate treatment → reassess source control, organism susceptibility, and dosing adequacy per relevant protocols, rather than mechanically extending the antibiotic course based on the number alone.

De-escalation: this protocol's entire content is, in effect, a de-escalation framework — using biomarker trajectory as one input (alongside fixed-duration evidence and clinical trajectory) to inform antibiotic discontinuation timing.

19. ICU Discharge Criteria — Not Directly Applicable

Cross-reference ICU Discharge Criteria & Step-Down and Antimicrobial Duration protocols; biomarker-specific consideration at discharge is limited to ensuring the planned antibiotic completion (whether biomarker-informed or fixed-duration) is clearly communicated to the receiving team.

20. Documentation & Medicolegal Checklist

• Baseline and serial PCT values documented
• Discontinuation decision rationale documented, integrating biomarker trend, source control status, and overall clinical trajectory
• Any deviation from biomarker-suggested discontinuation (continuing therapy despite a favorable biomarker trend, or vice versa) documented with clinical rationale

21. Key Guidelines

• Current antimicrobial stewardship guidance generally supports PCT-guided discontinuation as one reasonable tool within a broader stewardship strategy, while the 2026 reassessment commentary explicitly cautions that its marginal value is likely diminishing as fixed short-course therapy (cross-reference Antimicrobial Duration protocol) becomes further established as the baseline standard of care

22. Landmark Trials

23. Controversies

• The central, genuinely important controversy is not "does PCT work" but "how much additional value does it add on top of an already-improved baseline": this reframing — explicitly stated by the most recent expert commentary — is the key interpretive lens for this entire evidence base, and mirrors the ACURASYS-vs-ROSE pattern in the Neuromuscular Blockade in ARDS protocol, where a comparator's independent improvement (not the intervention's failure) substantially explains a shrinking effect size over time.
• CRP's clear inferiority to PCT in ADAPT-Sepsis resolves one genuine prior ambiguity (whether the cheaper, more available CRP could substitute for PCT) but does not fully explain the underlying biological reason for this difference — PCT's greater bacterial specificity is the leading, plausible explanation, though this was not independently, mechanistically confirmed within the trial itself.
• Suboptimal algorithm adherence remains a persistent, unresolved limitation across nearly the entire trial literature in this area, from PRORATA through ADAPT-Sepsis — this raises a genuine question of whether the intention-to-treat effect sizes reported across these trials systematically understate PCT's true biological signal (if adherence were perfect), or whether real-world adherence limitations should themselves be considered part of the intervention's realistic, achievable effect in actual practice rather than a correctable trial artifact.
• Future research direction: current expert consensus specifically suggests biomarker-guided care may hold more promise earlier in the sepsis care pathway (Emergency Department triage/diagnostic decisions) than in ICU-based discontinuation-timing decisions, where the marginal value proposition is explicitly described as narrowing — this represents a genuine, evidence-informed redirection of research priority rather than abandonment of the biomarker concept altogether.

24. References

1. Bouadma L, Luyt CE, Tubach F, et al; PRORATA trial group. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial). Lancet. 2010;375(9713):463-474.
2. de Jong E, van Oers JA, Beishuizen A, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial (SAPS). Lancet Infect Dis. 2016;16(7):819-827.
3. Shehabi Y, Sterba M, Garrett PM, et al. Procalcitonin algorithm in critically ill adults with undifferentiated infection or suspected sepsis (ProGUARD). Am J Respir Crit Care Med. 2014;190(10):1102-1110.
4. Wirz Y, Meier MA, Bouadma L, et al. Effect of procalcitonin-guided antibiotic treatment on clinical outcomes in intensive care unit patients with infection and sepsis patients: a patient-level meta-analysis of randomized trials. Crit Care. 2018;22(1):191.
5. Dark P, et al; ADAPT-Sepsis Collaborators. Biomarker-guided antibiotic duration for hospitalized patients with suspected sepsis: the ADAPT-Sepsis randomized clinical trial. JAMA. 2025.
6. Gupta S, Klompas M, Rhee C. Reassessing procalcitonin-guided antibiotic therapy in critically ill patients with sepsis: lessons from the ADAPT-Sepsis trial. Clin Infect Dis. 2026;82(3):453-458.
7. Pepper DJ, Sun J, Rhee C, et al. Procalcitonin-guided antibiotic discontinuation and mortality in critically ill adults: a systematic review and meta-analysis. Chest. 2019;155(6):1109-1118.
8. The Washington Manual of Critical Care, 4th ed. 2025 — antimicrobial stewardship and biomarker content.
9. ICU Protocols: A Step-wise Approach, 2nd ed. — antimicrobial therapy chapter.